CSL Behring AG, a global leader in biotherapeutics, is headquartered in Switzerland (CH) and operates extensively across Europe, North America, and Asia. Founded in 1904, the company has established itself in the biotechnology industry, specialising in the development and manufacture of innovative therapies for rare and serious diseases. CSL Behring is renowned for its high-quality plasma-derived products, including immunoglobulins, clotting factors, and albumin, which are essential for treating conditions such as haemophilia and immune deficiencies. The company’s commitment to research and development has led to significant advancements in patient care, positioning it as a trusted name in the healthcare sector. With a strong market presence and a dedication to improving patient outcomes, CSL Behring AG continues to achieve notable milestones, reinforcing its reputation as a pioneer in the biopharmaceutical landscape.
How does Csl Behring AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Csl Behring AG's score of 33 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Csl Behring AG reported total carbon emissions of approximately 347,000,000 kg CO2e. This figure reflects a slight increase from 2021, when emissions were about 324,000,000 kg CO2e, and a decrease from 2020, which recorded emissions of approximately 341,000,000 kg CO2e. The emissions data does not specify Scope 1, 2, or 3 emissions, indicating a lack of detailed breakdown in their reporting. Csl Behring AG is a current subsidiary of CSL Limited, which may influence its climate commitments and reporting practices. However, there are no specific reduction targets or climate pledges disclosed in the available data. The absence of documented reduction initiatives suggests that the company may still be in the early stages of formalising its climate strategy. Overall, while Csl Behring AG has shown fluctuations in its emissions over the past few years, the lack of specific reduction targets or commitments highlights an area for potential improvement in its climate action strategy.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Csl Behring AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.